Immunochemistry of lysosomal storage disorders

Clinical Chemistry

Volumn 52, Issue 9, 2006, Pages 1660-1668

  Parkinson Lawrence, Emma ^b   Fuller, Maria ^b   Hopwood, John J ^b   Meikle, Peter J ^b   Brooks, Doug A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ALPHA GLUCOSIDASE; BETA GLUCOSIDASE; CERAMIDE TRIHEXOSIDE; CHITOTRIOSIDASE; GANGLIOSIDE GM2; GANGLIOSIDE GM3; HEPARAN SULFATE; IDURONATE 2 SULFATASE; KERATAN SULFATE; LEVO IDURONIDASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; N ACETYLGALACTOSAMINE 4 SULFATASE; SPHINGOLIPID ACTIVATOR PROTEIN;

DISEASE SEVERITY; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; IMMUNOCHEMISTRY; LYSOSOME STORAGE DISEASE; MUCOPOLYSACCHARIDOSIS; NEWBORN SCREENING; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; IMMUNOLOGIC TESTS; INFANT, NEWBORN; LYSOSOMAL STORAGE DISEASES; NEONATAL SCREENING; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 33748288121     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.064915     Document Type: Review

References (80)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
2. Neufeld EF, Meunzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Vaile D, eds. The Metabolic and Molecular Basis of Inherited Disease, 8th ed. New York: McGraw-Hill, 2001:3421-52.
3. McCabe LL, McCabe ER. Complexity in genetic diseases: how patients inform the science by ignoring the dogma. Am J Med Genet A 2006;140:160-1.
4. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Vaile D, eds. The Metabolic and Molecular Basis of Inherited Disease, 8th ed. New York: McGraw-Hill, 2001;3635-68.
5. Hopwood JJ, Vellodi A, Scott HS, Morris CP, Litjens T, Clements PR, et al. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis 1993;16:1024-33.
6. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastures GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled multinational study of recombinant human α-L-iduronidase (Laronidase). J Pediatr 2004;144:581-8.
7. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Marcteaux-Lamy syndrome). J Pediatr 2004;144:574-80.
8. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebroside for Gaucher's disease. N Engl J Med 1991;324:1464-70.
9. Beck M. Agalsidase alfa-a preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs 2002;11:851-8.
10. Mehta A. Agalsidase alfa: specific treatment for Fabry disease. Hosp Med 2002;63:347-50.
11. Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002;91:98-9.
12. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Pediatrics 2004;113:e448-57.
13. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N- butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004;27:757-66.
14. Lachmann RH, Miglustat. Oxford GlycoSciences/Actelion [Review]. Curr Opin Investig Drugs 2003;4:472-9.
15. Moyses C. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci 2003;358:955-60.
16. Cox TM. Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr Suppl 2005;94:69-75.
17. Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 2005;15:43R-52R.
18. Loannou YA, Enriquez A, Benjamin C. Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2003;3:789-801.
19. Cheng SH, Smith AE. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 2003;10:1275-81.
20. McCown TJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 2005;5:333-8.
21. Griffey M, Macauley SL, Ogilvie JM, Sands MS. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther 2005;12:413-21.
22. Martino S, Marconi P, Tancini B, Dolcetta D, De Angelis MG, Montanucci P, et al. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet 2005;14:2113-23.
23. Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA. α-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 2004;338:453-62.
24. Lin H, Sugimoto Y, Ohsaki Y, Ninomiya H, Oka A, Taniguchi M, et al. N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta 2004;1689:219-28.
25. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 2002;99:15428-33.
26. Matsuda J, Suzuki O, Oshima A, Yamamoto Y, Noguchi A, Takimoto K, et al. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A 2003;100:15912-7.
27. Meikle PJ, Dean CJ, Grasby D, Bockmann MR, Whittle AM, Lang DL, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab 2006 April 3 (Epub ahead of print).
28. Li Y, Scott CR, Chamoles NA, Ghavani A, Pinto BM, Turecek F, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 2004;50:1785-96.
29. Wang D, Eadala B, Chamoles NA, Turecek F, Scott CR, Gelb MH, et al. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem 2005;51:898-900.
30. Clements PR, Brooks DA, Saccone GT, Hopwood JJ. Human α-L-iduronidase. I. Purification, monoclonal antibody production, native and subunit molecular mass. Eur J Biochem 1985;152:21-8.
31. Bielicki J, Freeman C, Clements PR, Hopwood JJ. Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties. Biochem J 1990;271:75-86.
32. Anson DS, Taylor JA, Bielicki J, Harper GS, Peters C, Gibson GJ, et al. Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase. Biochem J 1992;284:789-94.
33. Bielicki J, Hopwood JJ, Wilson PJ, Anson DS. Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme. Biochem J 1993;289:241-6.
34. Bielicki J, Hopwood JJ, Melville EL, Anson DS. Recombinant human sulphamidase: expression, amplification, purification and characterization. Biochem J 1998;329:145-50.
35. Montfort M, Garrido E, Hopwood JJ, Grinberg D, Chabas A, Vilageliul L. Expression and functional characterization of human mutant sulfamidase in insect cells. Mol Genet Metab 2004;83:246-51.
36. Zola H, Brooks DA. Techniques. In: Hurrell JGR, ed. Monoclonal hybridoma antibodies: techniques and applications. Boca Raton, FL: CRC Press, 1981:1-57.
37. Ashton U, Brooks DA, McCourt PA, Muller VJ, Clements PR, Hopwood JJ. Immunoquantification and enzyme kinetics of α-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients. Am J Hum Genet 1992;50:787-94.
38. Brooks DA, McCourt PA, Gibson GJ, Ashton LJ, Shutter M, Hopwood JJ. Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients. Am J Hum Genet 1999;48:710-9.
39. Perkins KJ, Byers S, Yogalingam G, Weber B, Hopwood JJ. Expression and characterization of wild type and mutant recombinant human sulfamidase. Implications for Sanfilippo (Mucopolysaccharidosis IIIA) syndrome. J Biol Chem 1999;274:37193-9.
40. Umapathysivam K, Whittle AM, Ranieri E, Bindloss C, Ravenscroft EM, van Diggelen OP, et al. Determination of acid α-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem 2000;46:1318-25.
41. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of α-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 2004;50:1979-85.
42. Parkinson EJ, Muller V, Hopwood JJ, Brooks DA. Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients. Mol Genet Metab 2004;81:58-64.
43. Hein LK, Meikle PJ, Dean CJ, Bockmann MR, Auclair D, Hopwood JJ et al. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots. Clin Chim Acta 2005;353:67-74.
44. Fuller M, Lovejoy M, Hopwood JJ, Meikle PJ. Immunoquantification of β-glucosidase: diagnosis and prediction of severity in Gaucher disease. Clin Chem 2005;51:2200-2.
45. Brooks DA. The immunochemical analysis of enzyme from mucopolysaccharidoses patients. J Inherit Metab Dis 1993;16:3-15.
46. Brooks DA. Application of monoclonal antibodies to the study of molecules in solution. In: Zola H, ed. Introduction to biotechniques series. Oxford, United Kingdom: BIOS Scientific Publishers 2000:81-100.
47. Ryall RG, Gjerde EM, Gerace RL, Ranieri E. Modifying an enzyme immunoassay of immunoreactive trypsinogen to use time-resolved fluorescence. Clin Chem 1993;39:224-8.
48. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Burgh H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992;119:961-75.
49. Tomatsu S, Okamura K, Taketani T, Orii KO, Nishioka T, Gutierrez MA, et al. Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr Res 2004;55:592-7.
50. McGlynn R, Dobrenis K, Walkley SU. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 2004;480:415-26.
51. Walkley SU. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 2004;15:433-44.
52. Chamoles NA, Blanco M, Gaggioli D. Diagnosis of α-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem 2001;47:780-1.
53. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001;308:195-6.
54. Chamoles NA, Blanco M, Iorcansky S, Gaggioli D Specola N, Casentini C. Retrospective diagnosis of GM1 gangliosidosis by use of a newborn-screening card. Clin Chem 2001;47:2068.
55. Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 2001;47:2098-102.
56. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Gaucher and Niemann-Pick diseases-enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002;317:191-7.
57. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002;318:133-7.
58. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 2004;347:97-102.
59. Umapathysivam K, Hopwood JJ, Meikle PJ. Determination of acid α-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem 2001;47:1378-83.
60. Fuller M, Brooks DA, Evangelista M, Hein LK, Hopwood JJ, Meikle PJ. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 2005;84:18-24.
61. Dean CJ, Bockmann MR, Hopwood JJ, Brooks DA, Meikle PJ. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood-spot and plasma samples. Clin Chem 2006; In Press.
62. Kotani M, Ozawa H, Kawashima I, Ando S, Tai T. Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides. Biochim Biophys Acta 1992;21:97-103.
63. Itoh K, Kotani M, Tai T, Suzuki H, Utsunomiya T, Inoue H, et al. Immunofluorescence imaging diagnosis of Fabry heterozygotes using confocal laser scanning microscopy. Clin Genet 1993;44:302-6.
64. Bekri S, Enica T, Ghafari G, Plaza I, Champenois G, Choukroun R, et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 2005;101:9.
65. Nakao S, Kodama T, Takenaka A, Tanaka Y, Yasumoto A, Yoshida T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64:801-7.
66. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11.
67. Yang Z, McMahon CJ, Smith LR, Bersola J, Adesina AM, Breinholt JP, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005;112:1612-7.
68. Meikle PJ, Brooks DA, Ravenscroft EM, Yan M, Williams RE, Jaunzems AE, et al. Diagnosis of lysosomal storage disorders: evaluation of a lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem 1997;43:1325-35.
69. Chang MH, Bindloss CA, Grabowski GA, Qi X, Winchester B, Hopwood JJ, et al. Saposins A, B, C, and D in plasma of patients with lysosomal storage disorders. Clin Chem 2000;46:167-74.
70. Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Paediatrics 2004;114:909-16.
71. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003;49:1797-817.
72. Brooks DA, McCourt PA, Gibson GJ, Hopwood JJ. Immunoquantification of the low abundance lysosomal enzyme N-acetylgalactosamine 4-sulphatase. J Inherit Metab Dis 1990;13:108-20.
73. Brooks DA, Harper GS, Gibson GJ, Ashton U, Taylor JA, McCourt PA, et al. Hurler syndrome: a patient with abnormally high levels of α-L-iduronidase protein. Biochem Med Metab Biol 1992;47:211-20.
74. Parkinson-Lawrence E, Turner C, Hopwood J, Brooks D. Analysis of normal and mutant iduronate-2-sulphatase conformation. Biochem J 2005;386:395-400.
75. Montfort M, Chabas A, Vilageliu L, Grinberg D. Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: Pathogenic changes and "modifier" polymorphisms. Hum Mutat 2004;23:567-75.
76. Sibilie A, Eng CM, Kim SJ, Pastores G, Grabowski GA. Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. Am J Hum Genet 1993;52:1094-101.
77. Tomatsu S, Dieter T, Schwartz IV, Sarmient P, Giugliani R, Barrera LA, et al. Identification of a common mutation in mucopolysaccharidosis IVA: correlation among genotype, phenotype, and keratan sulfate. J Hum Genet 2004;49:490-4.
78. Hua CT, Hopwood JJ, Carlsson SR, Harris RJ, Meikle PJ. Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders. Clin Chem 1998;44:2094-102.
79. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005;35:259-67.
80. Fusetti F, von Moeller H, Houston D, Rozeboom HJ, Dijkstra BW, Boot RG, et al. Structure of human chitotriosidase: implications for specific inhibitor design and function of mammalian chitinase-like lectins. JBC Papers in Press. Published on April 17, 2002 as Manuscript M201636200.